Investor Presentation H1 2023

13 Investor presentation First six months of 2023 Novo NordiskⓇ Semaglutide 2.4 mg demonstrated superior improvement on the primary endpoint of KCCQ-CSS vs placebo in the STEP HFPEF trial Superior improvement in KCCQ-CSS score in patients treated with semaglutide 2.4 mg Mean baseline KCCQ-CSS score: 56.7 Change in KCCQ-CSS (score) 20 20 15 10 5 16.6 8.7 Phase 3 trial STEP HFPEF with semaglutide 2.4 mg has been successfully completed in Q2 2023 • • Primary endpoints: KCCQ-CSS estimated treatment difference between semaglutide 2.4 mg and placebo of 7.8 Estimated treatment difference in body weight change between semaglutide 2.4 mg and placebo of -10.7% Safety: • The safety profile in HFPEF patients is consistent with previous data for semaglutide 2.4 mg 20 36 52 52* Time since randomisation (weeks) Semaglutide 2.4mg Placebo Note: Data shown is the treatment policy estimand. *Lines are based on observed data where the value denoted after 52 weeks is estimated mean value derived based on multiple imputation KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical summary score

View entire presentation